Adial Pharmaceuticals Inc (ADIL)

$0.14 -0.02 (-12.63%)
Market Cap 4.36M
Revenue (ttm) 0.00
Net Income (ttm) -13.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,288,100
Avg Vol 407,862
Day's Range N/A - N/A
Shares Out 27.78M
Stochastic %K 4%
Beta 1.26
Analysts Strong Sell
Price Target $2.17

Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 804 487 8196
Address:
4870 Sadler Road, Suite 300, Glen Allen, United States
FreeBeerTomorrow
FreeBeerTomorrow Feb. 6 at 5:42 AM
$ADIL * Adial Pharmaceuticals (ADIL) is trading on a split-adjusted basis today, Friday, February 6, 2026. Split Ratio: 1-for-25 . Based on the corporate announcement from February 3, 2026, the estimated new float for Adial Pharmaceuticals (ADIL) is approximately 1.1 million shares.
0 · Reply
TwongStocks
TwongStocks Feb. 5 at 9:13 PM
I am aware of four NASDAQ reverse split scheduled on Friday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Friday morning. $ADIL 1 for 25. Will reduce outstanding shares from approx 27.8m to approx 1.1m $ASST 1 for 20. Will reduce outstanding Class A shares from approx 1.05B to approx 52.48m and outstanding Class B shares from approx 197.91m to approx 9.9m $PRFX 1 for 5. Will reduce outstanding shares from approx 3.92m to approx 783k $RLYB 1 or 8. Will reduce outstanding shares from approx 42.24m to approx 5.28m
2 · Reply
blakely90
blakely90 Feb. 5 at 8:51 PM
AMST stock is disrupting the healthcare sector using AI. No debt + micro float with a low dilution risk. 5+ coming and this should be a $20 stock. News coming any day! Bottomed out under $2 is a steal. The CEO loaded $1M worth of shares at $3 and never has sold! Insiders will load up again here at lows! $BGMS $ADIL $GVH $SPRC $ILAG
0 · Reply
Magnificent77
Magnificent77 Feb. 5 at 5:45 PM
$ADIL still waiting..
1 · Reply
2TrustHim
2TrustHim Feb. 5 at 4:06 PM
$ADIL So Far $3.54 Open Tomorrow!!! This Is horrible!!! It Was Over $5.00 When They First Announced!!!
0 · Reply
Perfect_Thinking
Perfect_Thinking Feb. 5 at 2:59 PM
$ADIL ita fucked up, they are going for bankruptcy jerks
0 · Reply
2TrustHim
2TrustHim Feb. 5 at 1:23 PM
$ADIL This Gets Halted Tonight At 7:50pm Resumes Trading Tomorrow Morning At Split Event Stock Price. Too Bad they Couldn't Get some Crazy Partner News Wanting To Pay For Next Trial Because They Know How Valuable It Is!!!
0 · Reply
2TrustHim
2TrustHim Feb. 5 at 12:43 PM
$ADIL How Are We Funding The Next Clinical trial?
1 · Reply
dogood
dogood Feb. 5 at 11:39 AM
$ADIL they suppose to publish the data and run to $3 but no luck
0 · Reply
Risk1123
Risk1123 Feb. 5 at 12:37 AM
$ADIL o
0 · Reply
Latest News on ADIL
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

Feb 4, 2026, 9:35 AM EST - 1 day ago

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Feb 3, 2026, 4:05 PM EST - 2 days ago

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Oct 17, 2025, 9:00 AM EDT - 3 months ago

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Oct 9, 2025, 8:30 AM EDT - 4 months ago

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Sep 16, 2025, 8:00 AM EDT - 5 months ago

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Sep 3, 2025, 8:30 AM EDT - 5 months ago

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Aug 6, 2025, 8:00 AM EDT - 6 months ago

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Jul 16, 2025, 8:30 AM EDT - 7 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Jul 9, 2025, 8:30 AM EDT - 7 months ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Jun 25, 2025, 8:30 AM EDT - 8 months ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 8:30 AM EDT - 9 months ago

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

May 13, 2025, 8:30 AM EDT - 9 months ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

May 2, 2025, 11:48 AM EDT - 9 months ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

May 1, 2025, 8:30 AM EDT - 10 months ago

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Mar 4, 2025, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Feb 25, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Feb 19, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Feb 12, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jan 29, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Dec 3, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Nov 5, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Aug 7, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jul 23, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

May 29, 2024, 8:30 AM EDT - 1 year ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Apr 22, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Apr 10, 2024, 2:15 PM EDT - 1 year ago

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Apr 10, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Mar 1, 2024, 7:00 PM EST - 2 years ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Feb 28, 2024, 9:30 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Feb 15, 2024, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Feb 13, 2024, 9:15 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Jan 18, 2024, 8:30 AM EST - 2 years ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Dec 20, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Nov 29, 2023, 4:05 PM EST - 2 years ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 14, 2023, 5:02 PM EST - 2 years ago

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 24, 2023, 4:30 PM EDT - 2 years ago

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 20, 2023, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

Oct 19, 2023, 12:00 PM EDT - 2 years ago

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Oct 19, 2023, 10:30 AM EDT - 2 years ago

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

FreeBeerTomorrow
FreeBeerTomorrow Feb. 6 at 5:42 AM
$ADIL * Adial Pharmaceuticals (ADIL) is trading on a split-adjusted basis today, Friday, February 6, 2026. Split Ratio: 1-for-25 . Based on the corporate announcement from February 3, 2026, the estimated new float for Adial Pharmaceuticals (ADIL) is approximately 1.1 million shares.
0 · Reply
TwongStocks
TwongStocks Feb. 5 at 9:13 PM
I am aware of four NASDAQ reverse split scheduled on Friday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Friday morning. $ADIL 1 for 25. Will reduce outstanding shares from approx 27.8m to approx 1.1m $ASST 1 for 20. Will reduce outstanding Class A shares from approx 1.05B to approx 52.48m and outstanding Class B shares from approx 197.91m to approx 9.9m $PRFX 1 for 5. Will reduce outstanding shares from approx 3.92m to approx 783k $RLYB 1 or 8. Will reduce outstanding shares from approx 42.24m to approx 5.28m
2 · Reply
blakely90
blakely90 Feb. 5 at 8:51 PM
AMST stock is disrupting the healthcare sector using AI. No debt + micro float with a low dilution risk. 5+ coming and this should be a $20 stock. News coming any day! Bottomed out under $2 is a steal. The CEO loaded $1M worth of shares at $3 and never has sold! Insiders will load up again here at lows! $BGMS $ADIL $GVH $SPRC $ILAG
0 · Reply
Magnificent77
Magnificent77 Feb. 5 at 5:45 PM
$ADIL still waiting..
1 · Reply
2TrustHim
2TrustHim Feb. 5 at 4:06 PM
$ADIL So Far $3.54 Open Tomorrow!!! This Is horrible!!! It Was Over $5.00 When They First Announced!!!
0 · Reply
Perfect_Thinking
Perfect_Thinking Feb. 5 at 2:59 PM
$ADIL ita fucked up, they are going for bankruptcy jerks
0 · Reply
2TrustHim
2TrustHim Feb. 5 at 1:23 PM
$ADIL This Gets Halted Tonight At 7:50pm Resumes Trading Tomorrow Morning At Split Event Stock Price. Too Bad they Couldn't Get some Crazy Partner News Wanting To Pay For Next Trial Because They Know How Valuable It Is!!!
0 · Reply
2TrustHim
2TrustHim Feb. 5 at 12:43 PM
$ADIL How Are We Funding The Next Clinical trial?
1 · Reply
dogood
dogood Feb. 5 at 11:39 AM
$ADIL they suppose to publish the data and run to $3 but no luck
0 · Reply
Risk1123
Risk1123 Feb. 5 at 12:37 AM
$ADIL o
0 · Reply
Michaelthoaicaonguyen
Michaelthoaicaonguyen Feb. 4 at 10:41 PM
$ADIL $IXHL we may or we may not RS. The only difference between ADIL and IXHL is that they don’t have med, the team, and FTD. Speaking for pre or post RS. Dont spread fear before you understand the fundamentals of both company before you compare.
0 · Reply
verywellunknown
verywellunknown Feb. 4 at 10:03 PM
$IXHL this will drop to .15 when rs news come out; l, after that they release the eop2 and continue with the pr’s. At this point, it’s a waste of pr’s for the long run if they drop anything now.. See what happened to $ADIL
2 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 4 at 10:00 PM
$ADIL anyone that didn’t see this coming is blind
0 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 4 at 9:59 PM
$ADIL waiting for the RS crash
0 · Reply
Perfect_Thinking
Perfect_Thinking Feb. 4 at 9:40 PM
$ADIL files 8k, either on both ways lets watch, what its changes are..
0 · Reply
TwongStocks
TwongStocks Feb. 4 at 9:08 PM
$ADIL Equity Corporate Actions Alert #2026 - 68 Information Regarding the Reverse Stock Split and CUSIP Number Change for Adial Pharmaceuticals, Inc (ADIL) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-68 Adial Pharmaceuticals, Inc (ADIL) will effect a one-for-twenty five (1-25) reverse split of its Common Stock. The reverse stock split will become effective on Friday, February 6, 2026. In conjunction with the reverse split, the CUSIP number will change to 00688A304.
0 · Reply
Patrik605
Patrik605 Feb. 4 at 5:02 PM
$ADIL People don't know how to appreciate the potential of this company. I buy and believe in the success of this company. I just had the experience a loved one who had big problems with alcohol. The management could just change its approach and not promise even approximate dates if they are unable to meet the deadline. Small investors are the ones who are hit the hardest.
1 · Reply
Perfect_Thinking
Perfect_Thinking Feb. 4 at 4:24 PM
$ADIL ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026. The final legislation incorporates Senate Report 119-55, which includes a significant Congressional directive to the U.S. Food and Drug Administration (FDA)
0 · Reply
stockanalysis_
stockanalysis_ Feb. 4 at 4:06 PM
Losers Today: $AHMA $WTO $DSS $ADIL $NPT Save this screener: https://stockanalysis.com/markets/losers/?ref=saveontrading
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 4 at 4:04 PM
$ADIL gotta wait till after R/S to even consider playing this shitshow
0 · Reply
dln101
dln101 Feb. 4 at 3:02 PM
$ADIL markets a dump but maybe this gets pumped pre-split for old times sake: https://www.adial.com/adial-applauds-congressional-directive-advancing-alternative-clinical-trial-endpoints-for-substance-use-disorders-strengthening-regulatory-path-for-ad04/
0 · Reply
Lstreak
Lstreak Feb. 4 at 2:29 PM
$ADIL Who's going to take a guess on how low this will go down today?
0 · Reply